Caribou Biosciences, Inc. Class Action Lawsuit - CRBU

The filed complaint alleges that Caribou Biosciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) they had overstated CB-010’s safety, efficacy, and durability relative to approved autologous CAR-T cell therapies in treating patients with r/r B-NHL and/or LBCL, as well as CB-010’s overall clinical results and commercial prospects; (ii) Caribou was at significant risk of having insufficient cash, liquidity, and/or other capital to fund its current business operations, including preclinical research activities associated with the allogeneic CAR-NK platform; (iii) all the foregoing was likely to have a significant negative impact on Caribou’s business and operations; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

In order to be eligible to join the CRBU class action lawsuit, you must have incurred a loss on shares of Caribou Biosciences, Inc. purchased during the class period listed above.

If you suffered a loss in Caribou Biosciences, Inc. during the relevant time frame or pursuant to the relevant offering(s), you have until February 24, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.